Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment
November 13, 2023 at 09:01 AM EST
Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|